- Cambridge MA
- [email protected]
An experienced health care industry professional, Craig Fraser serves as the CEO and President of Discovery Labs, a public biopharmaceutical company dedicated to advancing the AEROSURF program for RDS in premature infants as well as other potential applications. Craig also serves on the Board of Directors for Discovery Labs.
Previously, he served as Chief Operating Officer with Aegerion Pharmaceuticals from 2011 to 2015. Craig Fraser’s work with the Cambridge, Massachusetts, biopharmaceutical company involved commercial efforts worldwide and spanned global access and supply, as well as life cycle management. Managing three presidents, Mr. Fraser guided the company launch and strategic diversification efforts and helped the firm achieve profitability within the 18 months of operations.
Mr. Fraser also has past experience with the pharmaceutical company Wyeth as Global Business Manager. He directed the launch of Tygacil in 64 countries, which resulted in the largest increase in IV antibiotic sales in two decades. This successful effort led to a position with Pfizer as president of global disease areas, guiding commercial development efforts spanning a portfolio of seven existing products and eight in-development entities. Craig Fraser exceeded revenue targets across the board in 2011 and effectively integrated specialty product lines.